Literature DB >> 32483738

Nanocapsule Delivery of IL-12.

Justin E Markel1, Ryan A Lacinski1, Brock A Lindsey2.   

Abstract

Interleukin(IL)-12 is a protein that activates T cells and macrophages to kill tumor cells. However, despite this cytokine showing strong antitumor activity in preclinical settings, translation to patients has been slowed by toxic side effects, poor distribution to peripheral tissues, and improper dosing regimens. Osteosarcoma (OS) is an aggressive primary tumor of bone that has shown particular responsiveness to recombinant (r)IL-12 in preclinical models. Poly(lactic-co-glycolic) acid (PLGA) nanospheres, an FDA-approved drug delivery vector, may be a viable delivery vector for transporting biologically active IL-12 to tissues without disturbing normal homeostasis. In this chapter, we explore the potential for using IL-12-loaded nanospheres (IL-12-NS, <1 μm in diameter) to treat cancer, describe the synthesis process, and examine a typical protein release profile while providing insight and future directions of nanoscale tumor immunotherapeutics.

Entities:  

Keywords:  IL-12; Immunotherapy; Nanocapsule; Nanoparticle; Osteosarcoma; PLGA

Mesh:

Substances:

Year:  2020        PMID: 32483738     DOI: 10.1007/978-3-030-43032-0_13

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  57 in total

1.  Generation of CD8 T cell memory is regulated by IL-12.

Authors:  Erika L Pearce; Hao Shen
Journal:  J Immunol       Date:  2007-08-15       Impact factor: 5.422

Review 2.  Macrophage activation and polarization.

Authors:  Fernando Oneissi Martinez; Antonio Sica; Alberto Mantovani; Massimo Locati
Journal:  Front Biosci       Date:  2008-01-01

Review 3.  Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity.

Authors:  G Trinchieri
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

4.  Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production.

Authors:  C L Nastala; H D Edington; T G McKinney; H Tahara; M A Nalesnik; M J Brunda; M K Gately; S F Wolf; R D Schreiber; W J Storkus
Journal:  J Immunol       Date:  1994-08-15       Impact factor: 5.422

5.  Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12.

Authors:  F Cavallo; E Di Carlo; M Butera; R Verrua; M P Colombo; P Musiani; G Forni
Journal:  Cancer Res       Date:  1999-01-15       Impact factor: 12.701

6.  Inhibition of angiogenesis in vivo by interleukin 12.

Authors:  E E Voest; B M Kenyon; M S O'Reilly; G Truitt; R J D'Amato; J Folkman
Journal:  J Natl Cancer Inst       Date:  1995-04-19       Impact factor: 13.506

7.  Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo.

Authors:  M K Gately; R R Warrier; S Honasoge; D M Carvajal; D A Faherty; S E Connaughton; T D Anderson; U Sarmiento; B R Hubbard; M Murphy
Journal:  Int Immunol       Date:  1994-01       Impact factor: 4.823

8.  Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4.

Authors:  N G Jacobson; S J Szabo; R M Weber-Nordt; Z Zhong; R D Schreiber; J E Darnell; K M Murphy
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

9.  Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells.

Authors:  R Manetti; P Parronchi; M G Giudizi; M P Piccinni; E Maggi; G Trinchieri; S Romagnani
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

10.  Antitumor and antimetastatic activity of interleukin 12 against murine tumors.

Authors:  M J Brunda; L Luistro; R R Warrier; R B Wright; B R Hubbard; M Murphy; S F Wolf; M K Gately
Journal:  J Exp Med       Date:  1993-10-01       Impact factor: 14.307

View more
  2 in total

1.  Synthesis, Characterization, and In Vivo Cytokinome Profile of IL-12-Loaded PLGA Nanospheres.

Authors:  Ryan A Lacinski; Justin E Markel; Jabeen Noore; Hillary G Pratt; Brock A Lindsey
Journal:  J Immunol Res       Date:  2022-04-14       Impact factor: 4.493

Review 2.  Oncolytic Adenoviruses for Cancer Therapy.

Authors:  Lorella Tripodi; Maria Vitale; Vincenzo Cerullo; Lucio Pastore
Journal:  Int J Mol Sci       Date:  2021-03-03       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.